talvey
janssen-cilag international n.v. - talquetamab - le myélome multiple - agents antinéoplasiques - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
talvey 3 mg/1.5 ml solution injectable
janssen-cilag ag - talquetamabum - solution injectable - talquetamabum 3 mg, natrii acetas ut natrii acetas trihydricus, acidum aceticum glaciale, saccharum, polysorbatum 20, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1.5 ml corresp. natrium 0.38 mg. - multiples myelom - biotechnologika
talvey 40 mg/1.0 ml solution injectable
janssen-cilag ag - talquetamabum - solution injectable - talquetamabum 40 mg, natrii acetas ut natrii acetas trihydricus, acidum aceticum glaciale, saccharum, polysorbatum 20, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 0.25 mg. - multiples myelom - biotechnologika
minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - agents antinéoplasiques - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).
minjuvi poudre pour solution
incyte corporation - tafasitamab - poudre pour solution - 200mg - tafasitamab 200mg - antineoplastic agents
minjuvi 200 mg poudre pour solution à diluer pour perfusion
incyte biosciences international sàrl - tafasitamabum - poudre pour solution à diluer pour perfusion - praeparatio cryodesiccata: tafasitamabum 200 mg, natrii citras dihydricus corresp. natrium 7.4 mg, acidum citricum monohydricum, trehalosum dihydricum, polysorbatum 20, pro vitro. - lymphome diffus à grandes cellules b (dlbcl) - biotechnologika
giotrif
boehringer ingelheim international gmbh - afatinib - carcinome, poumon non à petites cellules - agents antinéoplasiques - giotrif en monothérapie est indiqué pour le traitement ofepidermal growth factor receptor (egfr) tki-naïve des patients adultes atteints localement avancé ou métastatique non-small cell lung cancer (nsclc) avec l'activation de l'egfr mutation(s);localement avancé ou métastatique cbnpc de l'histologie épidermoïde de progresser ou après une chimiothérapie à base de platine.